Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma — Stella

Home/High Risk Smoldering Multiple Myeloma/Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma

View on ClinicalTrials.gov

Recruiting

Back to High Risk Smoldering Multiple Myeloma trials

Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

Spain

Hospital Clinico Universitario Salamanca, Salamanca

Key details

Phase

Safety & dosing

Sponsor

PETHEMA Foundation

Enrollment target

~20 participants

Started

September 2024

Primary completion

September 2032

Age range

18 Years and older

Last updated October 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.